Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

businesswire

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate – NEWSnet – News… as it used to be

More Press Releases

June 17, 2026

Nyxoah Receives $15 Million from the European Investment Bank

June 17, 2026

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

June 17, 2026

PSB Holdings, Inc. Announces Quarterly Cash Dividend of $0.18 Per Share

June 17, 2026

Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate

Nyxoah Receives $15 Million from the European Investment Bank

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

PSB Holdings, Inc. Announces Quarterly Cash Dividend of $0.18 Per Share

Great Southern Bancorp, Inc. announces quarterly dividend of $0.43 per common share